spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DX-88 

 HSMN NewsFeed - 21 Jun 2016
Keryx Biopharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Aug 2008
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2008
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2007
Dyax Announces Plans for Retirement of Steve Galliker as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 4 May 2007
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Apr 2007
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Biopharmacetuicals
 HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Positive Final Results from EDEMA2 Trial with DX-88 for the Treatment of Hereditary Angioedema Presented at ACAAI Meeting
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Dyax Announces the Appointment of Peggy Berry as Senior Vice President of Quality and Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2006
Dyax Provides Update on Regulatory Pathway for DX-88
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
DX-88
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.